Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
NCT04944706Phase 2Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of qishen yiqi dripping pills in Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Oct 2021; status: completed.
02
Drugs
qishen yiqi dripping pills
03
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Beyond the preview
Go deeper on NCT04944706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944706.